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40 word summary  
False-positive diagnoses are frequent in tuberculosis and have profound consequences, yet 
are usually overlooked in policy decision-making. We describe pathways and trade-offs 
involved, and their consequences for individuals, households and health systems. We then 
discuss steps to mitigate their impact.  
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Abstract  
To find the millions of missed tuberculosis (TB) cases, national TB programmes are under 
pressure to expand TB disease screening, and target populations with lower disease 
prevalence. Together with imperfect performance and application of existing diagnostic tools, 
including empirical diagnosis, broader screening risks placing individuals without TB on 
prolonged treatment. These false-positive diagnoses have profound consequences for TB 
patients and prevention efforts, yet are usually overlooked in policy decision-making. 
 
In this paper we describe the pathways to a false-positive TB diagnosis, including trade-offs 
involved in the development and application of diagnostic algorithms. We then consider the 
wide range of potential consequences for individuals, households, health systems, and 
reliability of surveillance data. Finally, we suggest practical steps that the TB community can 
take to reduce the frequency and potential harms of false-positive TB diagnosis and to more 
explicitly assess the trade-offs involved in the screening and diagnostic process.   
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1. Introduction 
1.1 Background  
To achieve ambitious targets to reduce incidence and deaths due to tuberculosis (TB), 
global and national policies emphasize the need to diagnose and treat a larger fraction of the 
10.4 million individuals who develop TB disease each year. [1, 2] For this reason, National 
Tuberculosis Programmes (NTPs) are under pressure to expand access to TB screening 
and diagnosis. [3] Similarly, the need for more sensitive diagnostic tools to detect patients 
earlier in the course of their disease and care seeking process has been highlighted, but 
increased sensitivity may come at the cost of reduced specificity. [4, 5] 
 
Current TB policy discussions, programme targets and indicators usually do not consider the 
risk of false-positive TB diagnoses [2, 6, 7], despite recognition of the issue in World Health 
Organization (WHO) recommendations of systematic screening programmes. [8]  
 
In this paper we describe how false-positive diagnoses are part of TB clinical practice, and 
their consequences for individuals, households, health systems and surveillance data. Our 
aim is to enable comprehensive discussions on the trade-offs involved for expanded TB 
screening programmes. We then propose concrete actions that can be undertaken to 
mitigate the negative effects of false-positive TB diagnosis.  
1.2 Definition of false-positive TB diagnosis  
We define a false-positive TB diagnosis as one where an individual, who does not have 
active TB disease, incorrectly receives a diagnosis of TB disease. In this vein, we use the 
term false-positive (a term widely used in clinical epidemiology) to suggest the absence of 
active TB disease, not the absence of symptoms or the absence of other non-TB illness 
(e.g., bacterial pneumonia, obstructive lung disease). Importantly also, we use this term also 
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to apply only to the diagnostic process itself, not the individual undergoing diagnosis – as the 
latter may be stigmatising. [9, 10] 
1.3 Path towards false-positive TB diagnosis  
Figure 1 outlines the screening and diagnostic pathway for TB. A screening population is 
composed of individuals with and without TB. Some individuals without TB may have an 
underlying illness that presents with similar symptoms to those of TB. A diagnostic algorithm, 
with imperfect sensitivity and specificity, is then applied to the screening population. All those 
diagnosed with TB (correctly or not) are eligible to start treatment and should be notified as 
part of national and global surveillance.  
 
The proportion and the underlying reasons for false-positive TB test results vary, and are 
highly setting-dependent as local guidelines and policy will dictate different diagnostic 
algorithms in different populations. Differences in background prevalence of TB or co-
morbidity patterns (e.g. HIV, silicosis) as well as human performance and laboratory capacity 
can influence test performance and result interpretation. A key example is empirical (or 
‘clincal’) diagnosis, where TB is diagnosed (and treatment is started) in the absence of a 
recorded positive bacteriological test. Empirical diagnosis accounted for 43% of all cases 
reported to WHO globally in 2017. [7] Decisions to treat empirically are based on a mix of 
symptomatic presentation, co-morbidities, chest X-ray and other ancillary tests, non-
response to other therapeutic maneuvers (e.g., trials of broad-spectrum antibiotics), and 
individual clinician assessment – all of which vary from one population (and one provider) to 
the next. Empirical diagnosis is a critical part of the diagnostic arsenal, especially in low-
resource settings where health workers may see a high number of TB patients to inform their 
clinical judgement. However, the limited data available suggests that the sensitivity and 
specificity of empirical diagnosis is both highly variable and suboptimal. A multi-country 
diagnostics trial found sensitivity ranged from 16% to 44.4% and the specificity ranged from 
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86.9% to 95.3% across study sites, and was significantly influenced by coverage of chest X-
Ray [11].  
 
In high-income settings, where greater resources are available, initial screening and 
diagnostic approach are strongly tilted towards increasing specificity, thus decreasing the 
risk of a false-positive diagnosis despite the low prior of TB in the screening population.  
 
By contrast, TB diagnosis in a rural health centre in a resource-limited setting will often rely 
on smear microscopy, symptoms and clinical examinations only. Variability in the accuracy 
of empirical diagnosis – and the attendant risk of false-positive diagnosis – is likely to be 
enhanced in the highly heterogenous private sector. A study in India found that TB diagnosis 
was more often reliant on clinical opinion and less on bacteriological confirmation. [12]  
 
As countries look to expand screening programmes beyond individuals self-reporting to TB 
clinics (i.e. passive case finding), the screening population will likely have a lower prevalence 
of disease, either at the start, or the prevalence could drop after repeated rounds of 
screening. Table 1 illustrates how such a drop will also affect the rates of false-positive 
diagnoses, and why different algorithms may therefore need to be considered in these 
screening programmes as compared to evaluating self-reported individuals. If a standard 
algorithm of symptom screen, sputum microscopy and empirical diagnosis (Algorithm 1, 
column 2 and 3) was used, a drop from the current approximate 10% prevalence among 
patients submitting sputum for TB diagnosis in healthcare settings to a high-risk screening 
population with 1% prevalence (1000/100,000), can result in more than 70% of all TB 
diagnoses being made among people who do not have underlying TB disease, i.e. nearly 
2.5 false-positive TB diagnoses for each true-positive.  
 
To mitigate the high probability of a false-positive diagnosis, screening programmes could 
look to increase the specificity, or consider improving sensitivity to diagnose more true-
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positive cases. Figures 2a-b show how the positive predictive value (i.e. the proportion of 
individuals with TB diagnosis that actually have TB disease) changes with sensitivity (Figure 
2a) or specificity (Figure 2b). From these, it becomes clear that improvements in sensitivity 
will have limited impact on the PPV, and that prevalence in the screening population is the 
key driver. However, the PPV is much more dependent on small increases or declines 
across a narrow range in specificity (Figure 2b).   
 
Ideally, diagnostic algorithms in screening programmes would improve both sensitivity and 
specificity, for example resembling the protocols used in prevalence surveys (Table 1, 
Algorithm 2, column 4 and 5). However, even with an algorithm of 99.0% specificity, a 
screening population with a 0.5% prevalence (500/100,000) of TB would lead to the number 
of false-positive TB diagnoses outnumbering true-positive diagnoses.  
 
It is important to note that these scenarios use best available, but sometimes weak, current 
estimates for the sensitivity and specificity of all tests, including empirical diagnosis [8]. 
However, in the absence of wide application of improved diagnostic tools, the stronger the 
external push to increase the number of TB diagnoses (whether by using more sensitive 
tests or empirically treating more people), the more specificity will become compromised, 
and the higher the number of false-positive diagnoses will be.  
2. Consequences of false-positive TB diagnosis  
2.1 The Individual  
False-positive diagnoses for TB are usually considered to have minimal long-term health 
implications for patients. However, they can in fact lead to substantial negative 
consequences – consequences that generally will not be later corrected. Specifically, 
patients testing false-positive for active TB will almost invariably be recommended for a 
treatment course that currently lasts a minimum of six months. Not only does TB treatment 
 7 
carry a non-negligible risk of adverse clinical events (for example, at least a one-in-fifty risk 
of clinically relevant hepatotoxicity), [13] but patients also incur substantial costs. Even when 
clinical services are provided to the patient for free (as is the case in many settings), patients 
still incur high non-clinical costs, including transportation, food, childcare, and lost wages. In 
a systematic review of patient costs including 14 studies in low-income countries, the mean 
direct patient cost (plus productivity loss) was estimated at $248 per patient [14]; a second 
systematic review estimated that total patient costs of TB averaged 58% of annual patient 
income, with half of those costs occurring after treatment [15]. In addition, undergoing TB 
treatment (especially when directly observed and in poor structural conditions) often results 
in damaging social consequences – including stigma, isolation from families, gender 
discrimination, loss of hope, and disrespect. [16] 
 
Less well studied are the consequences of missing other conditions that may be falsely 
diagnosed as TB. One small study has suggested an increase in mortality among HIV-
positive Ugandan adults with false-positive TB microscopy results [17], though this result 
was not statistically significant. Underlying conditions in individuals falsely diagnosed as 
having TB can range from bacterial pneumonia to lung cancer [18]. In the case of 
pneumonia – potentially the most common missed diagnosis – rifampin has some activity 
against the most common bacterial pathogens isolated [19], but other antimicrobial regimens 
are more effective. Many of these “missed” conditions are more rapidly progressive or fatal 
than tuberculosis itself, meaning that in many such cases, the consequences of delayed 
diagnosis resulting from a false-positive TB diagnosis will be equally (if not more) clinically 
devastating than those of false-negative TB diagnoses.  
 
In contrast to perceptions around false-positive diagnoses, the consequences of false-
negative diagnoses of TB are often portrayed as being fatal. As a result, studies of relative 
harms often suggest that a large number of false-positive diagnoses should be tolerated to 
avert a single false-negative diagnosis (with ratios as high as 30:1). [20] However, indirect 
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evidence suggests that most individuals with TB initially diagnosed as false-negative often 
later start treatment – either empirically or through other diagnostic tests. For example, 
results from clinical trials suggest that the advantages of using more sensitive diagnostic 
testing with Xpert MTB/RIF relative to sputum smear microscopy is at least partially 
counterbalanced by existing practices of empirical treatment (i.e., treatment of patients 
testing false-negative by Xpert). [21-24]  
 
Thus, while much of the TB literature has focused on the potential consequences to patients 
of false-negative diagnoses, the implications of false-positive diagnoses – from life-
threatening side effects to social stigmatisation to morbidity and mortality from other 
conditions – may be no less dire. The relative harm of false-positive versus false-negative 
diagnosis is an important consideration in, for example, decisions to screen for TB in lower-
risk populations or to use more sensitive, less specific tests (e.g., Xpert Ultra). [25] 
2.2. Household  
Households of individuals who receive false-positive diagnoses are also negatively affected. 
Prolonged treatment for TB leads not only to additional healthcare-related expenditures but 
also to loss of income for the household, which can cause households to experience 
catastrophic costs. [15, 26] Such a descent into poverty will have a substantial and long-term 
impact on all household members including education, income and health. [27] 
2.3 Health System  
Recent modelling analyses have focused on the impact of resource constraints in the health 
system on the ability to implement ambitious interventions, including constraints on health 
care staff and beds in the multi-drug resistant TB (MDR-TB) wards [28-30]. In the context of 
limited drug supply and health care workers, treating patients who received false-positive TB 
diagnoses may substantially worsen care for patients in other segments of the healthcare 
system.  
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2.4 Surveillance and burden estimation  
Programme performance will be overestimated in the presence of false-positive diagnosis, 
as treating false-postively diagnosed patients will have no impact on the TB epidemic. As 
highlighted by Table 1, reported notifications can easily be misleading as an indicator for the 
success of an expanded screening strategy – an increased number of notifications may 
simply represent a dramatic increase in the number of false-positive diagnoses.  
In addition, those notified and initiating treatment are assumed to have been at risk of dying 
due to TB. If a substantial proportion of this cohort does not have TB disease (and instead 
has less serious conditions), observed mortality rates may be artificially low, leading to 
overestimates of treatment success both on country and global level.  
 
Such unintentional misrepresentations can, when revealed through for example prevalence 
surveys, undermine faith from domestic and international funders of the national TB 
response.  
 
These issues also affect burden estimation and reporting at the global level. Current TB 
estimation methods by WHO and Institute for Health Metrics and Evaluation do not consider 
false-positive diagnoses, and instead assume all notified cases represent patients with a 
true-positive diagnosis. [31, 32] As a consequence the inclusion of false-positive diagnoses 
artificially increases official incidence estimates, and leads to an underestimation of the gap 
between incident cases and those notified for treatment. [7, 32]  
3. What can be done  
3.1 Acknowledge the problem  
The first step will be to explicitly include the challenge of false-positive TB diagnosis in TB 
policy discourse. In these discussions, policy bodies should explicitly consider false-positive 
TB diagnosis as a challenge that already inflates reported TB notifications, and acknowledge 
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that these distortions may increase further as new ambitious programmes are rolled out. In 
addition, efforts should be made to estimate the proportion of false-positive TB diagnoses in 
surveillance data as part of country-level reporting to WHO-GTB and the Global Fund 
against AIDS, Tuberculosis and Malaria. As multiple high-level indicators for policy 
evaluation and advocacy may be strongly affected by false-positive diagnosis, an explicit 
evaluation of the potential bias introduced in different settings would be sensible.  
 
To inform such and future evaluations, a concrete step could be to generate a quantitative 
estimate for the sensitivity and specificity of the diagnostic algorithms as applied in each 
country, and then to use those estimates to inform estimates of false-positive diagnoses (as 
in Table 1). While heterogeneity in diagnostic test performance and implementation is likely, 
strengthening the current data through for example programmatic reviews and national 
strategic planning is of high value. Outcomes could include identified opportunities for 
improvement (e.g. in the protocol for empirical diagnosis) and data strengthening, better 
estimates of the proportion false-positive TB diagnoses, and more realistic estimates of 
country programme performance.   
 
3.2 Evaluate trade-offs in screening programmes  
As outlined in the previous section, false-positive TB diagnoses follow from the trade-off 
between potential positive and negative effects of real-life screening and diagnostic 
processes. We propose that rather than focusing solely on the positive potential of new 
screening strategies, new strategies should be evaluated through a comprehensive 
conceptual framework that also acknowledges the potential negative consequences of false-
positive diagnosis.  
 
Here, any change in screening strategies should be evaluated in terms of delivering the 
correct diagnosis for all individuals evaluated for TB, including those without TB. In other 
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words, in a setting where a more sensitive screening test is being considered, programmes 
could explicitly consider the aim of increasing the number of individuals who receive a true 
positive diagnosis instead of a false negative diagnosis and balance this against the number 
of individuals who may receive a false positive rather than a true negative diagnosis. Where 
more specific confirmatory testing is being considered, it is important to consider the number 
of false positive diagnoses that could be averted, balancing this against the number of true 
positive diagnoses that may be missed.  
 
The practical consequences of these choices are shown Figure 2 and the final three 
columns in Table 1 where the balance between additional true positive and true negative 
diagnoses shifts notably as the prevalence of disease changes, an observation masked by  
simply counting the number of additional TB diagnoses.  
 
With each policy decision around e.g. diagnostic approach or population screened, the 
relative health and financial cost for each diagnosis should be considered. Together, these 
will provide a comprehensive overview of the cost and benefit of a specific change, for 
example, informing the choice to try and replace empirical diagnosis with microbiological 
testing.  
 
In this framework, the trade-offs between sensitivity and specificity of the diagnostic 
algorithm, as well as the disease prevalence in the screening population, become more 
explicit. Moving beyond a simple comparison of sensitivity and specificity, the potential 
performance of new tests or case finding approaches could be simply summarized in the 
change in the ratio false-positive/true-positive across different prevalences of disease in the 
target population (see Table 1). Alternatively, more sophisticated decision curve analyses 
can incorporate additional heterogeneity and complexity in given settings. [25, 33] 
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While quantifying the consequences of each trade-off more comprehensively is critical, 
decisions regarding acceptable levels of false-positive diagnosis (relative to the number of 
true-positive diagnoses) will still need to be made. Such choices are also multidimensional 
and highly setting-specific, but explicitly considering these trade-offs represents an important 
first step.  
 
3.3 Research  
Work is needed to provide quantitative estimates for the weight a false-positive diagnosis 
should carry compared to a false-negative, or example, by quantifiying the costs and quality-
adjusted life years lost through incorrect diagnoses for individuals with vs without TB. Such 
work could examine the acceptable number of false-positive TB diagnoses for one additional 
true positive diagnosis, across settings. A number of papers have already highlighted strong 
discrepancies between perceived and data-based thresholds, as well as variation between 
the preferences of clinicians, public health officials and patients. [20, 34, 35].  
 
Another key area of research is to improve the empirical data underlying our current 
estimates of test performance, particularly the accuracy of empirical diagnosis and the 
specificity of “definitive’ diagnostic tests. While reviews [8] and examples of research exist 
[36], substantial uncertainty remains on the baseline performance of key tests, particularly as 
implemented in actual field settings. One example is the specificity of sputum smear, which 
has shown great variability in recent prevalence surveys, with up to 43% of smear-positive 
cases not confirmed by culture. [37] Again, some of these data will be setting-specific, in 
particular for empirical diagnosis. But a better understanding of how the performance 
depends on specific factors (e.g. background TB and HIV prevalence, use/availability of 
Xray, etc..) will help inform estimates. Recent studies have also highlighted the value of 
considering urine LAM and C-reactive Protein as part of TB screening in high-risk HIV 
positive populations. [38, 39]  
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3.4 Test application  
False positive TB diagnoses are not exclusively caused by suboptimal diagnostic accuracy, 
but are also driven by pre- and post-analytic errors, adminstrative errors as well as 
laboratory errors in handling of reagents and/or maintance of instruments. By strengthening 
domestic and international laboratory networks, TB diagnostics can be embedded in well-
functioning systems of training and quality control to help reduce false-positive TB 
diagnoses.  
 
4. Conclusion  
As the TB community looks to close the diagnostic gap through expanded screening and 
improved diagnostic tools, it is important to acknowledge false-positive TB diagnoses as part 
of current reality and consequence of expanded screening efforts. By recognizing and 
addressing the size as well as consequences of false-positive diagnoses, we can improve 
clinical outcomes for individuals and focus the limited resources available to ‘End TB’ to 
achieve stronger population impact.  
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Tables 
Table 1: False-positive TB diagnoses in hypothetical screening programmes 
 
Prevalence in 
screening 
population 
Algorithm 1: 
Any symptom --> 
smear --> empirical 
diagnosis 
Algorithm 2: 
Any symptom or X-
Ray --> GeneXpert 
 
Impact of new algorithm in 
Population = 100,000 
 PPV Ratio TP / 
FP 
PPV Ratio TP / 
FP 
Change in # 
TB 
diagnoses 
From FN 
to TP 
From FP to 
TN 
10% 73% 1:0.37 95% 1:0.05 +2261 3767 1506 
5% 61% 1:0.64 90% 1:0.11 +1369 2271 902 
1% 29% 1:2.50 64% 1:0.56 +157 526 369 
0.5% 17% 1:4.78 67% 1:1.13 -30 268 298 
0.15% 6% 1:15.29 21% 1:3.78 -166 82 248 
 
PPV = Posititive Predictive Value, i.e. % of individuals with TB diagnosis that actually have TB 
disease, FP = False-positive, TP = True-positive. Cell highlighting shows scenarios where the majority 
of diagnosed cases are expected to be true positive cases (green) or false-positive TB diagnosis 
(red).  
 
Algorithm 1: Individuals who are positive on screen with any symptom are tested for TB using 
sputum smear microscopy. A proportion of individuals with a negative smear continue to empirical 
diagnosis. The probability of being referred towards empirical diagnosis following a negative smear is 
negatively correlated with the prevalence of disease in the screening population between 80% and 
5%, as the negative predictive value following a negative smear decreases. 
 
Algorithm 2: Individuals who screen positive either with any symptom of show any abnormality on 
Chest X-Ray are tested with GeneXpert. Here we assume no empirical diagnosis so that individuals 
with no symptoms and no CXR abnormality or a negative GeneXpert result are ruled out from having 
TB disease. 
 
In both scenarios, we assume that the prevalence of smear positive TB disease is negatively 
correlated with the prevalence of disease in the screening population between 60% and 40% to reflect 
expanding case-detection towards the general population, therefore detecting earlier disease. The 
screening and specificity values were obtained from [8] and  [11] 
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Figure legends 
 
Figure 1: Screening and diagnostic pathway for tuberculosis (TB)  
 
From a general population, a screening population is formed from individuals with (orange) and 
without TB (green). The diagnostic algorithm is applied to the screening population, categorising 
individuals into those recommended for TB treatment (following a true-positive or false-positive 
diagnosis) or not. The contribution of false-positive TB diagnoses is mostly driven by the prevalence 
of TB in the screening population and the specificity of the diagnostic algorithm (see Table 1). The 
dashed arrows on the right highlight the two processes that new screening or diagnostic strategies 
aim to achieve: orange = convert false-negative diagnoses into true-positive, green = convert false-
positive diagnoses into true-negative diagnoses. 
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Figure 2a-b: Change in positive predictive value by varying sensitivity (2a) or 
specificity (2b)  
 
Figures show relationship between Positive Predictive Value (% of individuals with TB diagnosis that 
actually have TB disease) and prevalence of disease in screening population for combinations of 
sensitivity and specificity. Lines in Figure 2a (left) show how relationship changes if specificity for 
algorithm 1 (Table 1) remains constant at 97%, but sensitivity increases. Lines in Figure 2b (right) 
show how relationship changes if sensitivity remains constant at 53%, but specificity increases or 
decreases. See Table 1 for details of algorithm 1.  
